FOUNTAIN BIOPHARMA INC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.75 TWD | -0.30% |
|
-1.93% | -.--% |
| 1 day | -0.30% |
| Managers | Title | Age | Since |
|---|---|---|---|
Hui Fang Huang
CEO | Chief Executive Officer | - | - |
Wen Tzu Hsiao
DFI | Director of Finance/CFO | - | 16-06-12 |
Nien Yi Chen
IRC | Investor Relations Contact | - | 12-02-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chun Hung Chen
BRD | Director/Board Member | 69 | 17-09-05 |
Yung Hung Chung
BRD | Director/Board Member | - | 17-09-05 |
Hui Fang Huang
CEO | Chief Executive Officer | - | - |
Fountain Biopharma Inc. is a Taiwan-based company principally engaged in the research, development and sales of antibody drugs. The Company's main products include an anti-allergy single-injection antibody, FB825-Anti-CmX; a single-injection antibody, FB704A-Anti-IL6; a biosimilar drug, FB317-Omalizumab, and a biosimilar drug, FB121-Ibalizumab. The Company has not generated any revenue for the past two years.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 161M | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- 4159 Stock
